Sequential Bevacizumab-based therapy in metastatic colorectal cancer (mCRC): results of a treatment sequencing cost analysis

被引：0
|
作者：
Rautenberg, T. [1 ]
Siebert, U. [2 ]
Arnold, D. [3 ]
Bennouna, J. [4 ]
Kubicka, S. [5 ]
Walzer, S. [1 ]
Ngoh, C. [6 ]
机构：
[1] AiM Assessment Med GmbH, Lorrach, Germany
[2] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria
[3] Univ Hosp, Hubertus Wald Tumor Ctr, UCCH, Eppendorf, Germany
[4] Inst Cancerol Quest, Nantes, Saint Herblain, France
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] F Hoffmann La RocheLa Roche AG, Basel, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Body fatness and bevacizumab-based therapy in metastatic colorectal cancer
    Renehan, Andrew G.
    GUT, 2010, 59 (03) : 289 - 290
  • [2] Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
    Manzoni, M.
    Rovati, B.
    Ronzoni, M.
    Loupakis, F.
    Mariucci, S.
    Ricci, V.
    Gattoni, E.
    Salvatore, L.
    Tinelli, C.
    Villa, E.
    Danova, M.
    ONCOLOGY, 2010, 79 (3-4) : 187 - 196
  • [3] Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study
    Artaç M.
    Coşkun H.Ş.
    Dane F.
    Karabulut B.
    Korkmaz L.
    Karaağaç M.
    Çabuk D.
    Karabulut S.
    Faruk Aykan N.
    Doruk H.
    Avcı N.
    Turhal N.S.
    Journal of Gastrointestinal Cancer, 2016, 47 (3) : 264 - 272
  • [4] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
    Xu, Ran
    Xu, Chen
    Liu, Chuntong
    Cui, Can
    Zhu, Jing
    ONCOTARGETS AND THERAPY, 2018, 11 : 8605 - 8621
  • [5] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer A meta-analysis
    Ma, Hongbo
    Wu, Xiaoli
    Tao, Miaomiao
    Tang, Nan
    Li, Yanyan
    Zhang, Xianquan
    Zhou, Qi
    MEDICINE, 2019, 98 (50)
  • [7] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [8] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [9] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] COST ANALYSIS OF METASTATIC COLORECTAL CANCER TREATMENT WITH BEVACIZUMAB AND CETUXIMAB
    Maria Vieitez, Jose
    Oyaguez, Itziar
    Angel Casado, Miguel
    ANNALS OF ONCOLOGY, 2011, 22 : v84 - v84
12345